APEX is a pharmaceutical company focused on developing psychedelic-based pharmaceuticals for depression in Veterans with PTSD. They have multiple drug candidates in development, including a low-dose synthetic psilocybin-derived treatment. APEX aims to receive Health Canada approval through a strategic clinical program. The company is driven by an experienced leadership team and is advocating for expanded access to mental health care for Veterans. They are also laying the groundwork to develop innovative pharmaceuticals for a range of mental health conditions. Learn more at apexlabs.com.